Catalyst Pharmaceutical Inc. (CPRX) Stock Price

CPRXStock

$0.00−17.44%52W

Market Cap—

P/E17.99x

PEG Ratio0.92

Div yield—

Beta0.58

CPRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)30.78%

Price vs S&P 500 (4W)0.78%

PEG Ratio0.92

VGM Score64.71

P/E Ratio (Annual)17.99x

P/CF (Annual)18.47x

Book Value / Share (Quarterly)$8.29

P/TBV (Annual)3.49x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)40.10%

Cash Flow / Share (Quarterly)$1.70

Price vs S&P 500 (YTD)24.67%

Gross Margin (TTM)85.96%

Net Profit Margin (TTM)37.08%

EPS (TTM)$1.74

10-Day Avg Trading Volume3.49M

EPS Excl Extra (TTM)$1.74

Revenue Growth (5Y)37.67%

EPS (Annual)$1.68

ROI (Annual)22.46%

Gross Margin (Annual)85.19%

Net Profit Margin (5Y Avg)30.90%

Cash / Share (Quarterly)$6.19

P/E Basic Excl Extra (TTM)17.42x

Revenue Growth QoQ (YoY)5.63%

EPS Growth (5Y)18.99%

P/E Normalized (Annual)17.99x

ROA (Last FY)19.41%

Revenue Growth TTM (YoY)11.65%

EBITD / Share (TTM)$2.40

ROE (5Y Avg)22.03%

Operating Margin (TTM)44.83%

Cash Flow / Share (Annual)$1.70

P/B Ratio3.81x

P/B Ratio (Quarterly)2.99x

Net Income / Employee (Annual)$1,177,600

EV / Revenue (TTM)5.19x

Net Interest Coverage (TTM)-91.00x

ROA (TTM)20.71%

EPS Growth QoQ (YoY)12.37%

EV / EBITDA (TTM)10.14x

EPS Incl Extra (Annual)$1.68

Current Ratio (Annual)6.08x

Quick Ratio (Quarterly)6.72x

3-Month Avg Trading Volume2.18M

52-Week Price Return-17.44%

EV / Free Cash Flow (Annual)14.86x

P/E Incl Extra (TTM)17.42x

Revenue / Employee (TTM)$3,280,000

Tangible BV / Share (Quarterly)$7.29

P/S Ratio (Annual)6.54x

Asset Turnover (Annual)0.53x

52-Week High$32.56

Operating Margin (5Y Avg)38.00%

EPS Excl Extra (Annual)$1.68

Tangible BV CAGR (5Y)27.04%

26-Week Price Return39.46%

Quick Ratio (Annual)5.70x

13-Week Price Return26.26%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.10x

Enterprise Value$3.10B

Revenue / Share Growth (5Y)32.78%

Asset Turnover (TTM)0.56x

Book Value / Share Growth (5Y)36.66%

Revenue / Employee (Annual)$3,236,200

Inventory Turnover (Annual)3.08x

Pretax Margin (Annual)48.14%

Cash / Share (Annual)$5.79

3-Month Return Std Dev27.21%

Gross Margin (5Y Avg)85.31%

Net Income / Employee (TTM)$1,216,100

EBITDA CAGR (5Y)48.13%

EBITDA Interim CAGR (5Y)52.98%

ROE (Last FY)22.46%

Net Interest Coverage (Annual)-17.00x

EPS Basic Excl Extra (Annual)$1.68

P/FCF (TTM)18.52x

Receivables Turnover (TTM)5.91x

EV / Free Cash Flow (TTM)14.89x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$1.74

Receivables Turnover (Annual)6.14x

ROI (TTM)23.65%

P/S Ratio (TTM)6.46x

Pretax Margin (5Y Avg)40.43%

Revenue / Share (Annual)$4.63

Tangible BV / Share (Annual)$6.71

Forward P/E14.33x

Free OCF CAGR (5Y)35.90%

Price vs S&P 500 (52W)-27.07%

P/E Ratio (TTM)17.42x

EPS Growth TTM (YoY)10.72%

Year-to-Date Return34.92%

5-Day Price Return0.06%

EPS Normalized (Annual)$1.68

ROA (5Y Avg)18.52%

Net Profit Margin (Annual)36.39%

Month-to-Date Return0.19%

Cash Flow / Share (TTM)$0.77

EBITD / Share (Annual)$2.32

EPS Growth (3Y)31.19%

Operating Margin (Annual)43.77%

P/CF (TTM)18.51x

ROI (5Y Avg)22.03%

P/E Excl Extra (TTM)17.42x

EPS Basic Excl Extra (TTM)$1.74

P/TBV (Quarterly)3.39x

P/B Ratio (Annual)3.01x

Inventory Turnover (TTM)3.06x

Pretax Margin (TTM)49.66%

Book Value / Share (Annual)$7.79

Price vs S&P 500 (13W)15.61%

Net Margin Growth (5Y)-10.39%

Beta0.58x

P/FCF (Annual)18.48x

Revenue / Share (TTM)$4.70

ROE (TTM)23.65%

52-Week Low$19.90

vGradeC

gGradeB

mGradeB

vgmGradeB

CPRX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q1 2026	May 11, 2026	$0.64	$0.79	+22.91%(+$0.15)
Q4 2025	Feb 25, 2026	$0.50	$0.68	+35.70%(+$0.18)
Q3 2025	Nov 5, 2025	$0.54	$0.68	+26.34%(+$0.14)
Q2 2025	Aug 6, 2025	$0.54	$0.68	+25.01%(+$0.14)

CPRX Analyst Recommendations

Apr 2026

May 2026

Jun 2026

Jul 2026

4.43

3.67

2.44

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CPRXCatalyst Pharmaceutical Inc.	C	B	B	6.5x	11.7%	86.0%	19.0%	$0.00
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Catalyst Pharmaceutical Inc.

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases. The company commercializes three FDA-approved drugs: FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). It pursues growth through acquiring accretive assets, including clinical-stage candidates with established proof of concept.